Cargando…

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective

Detalles Bibliográficos
Autor principal:	Ghosh, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196287/ https://www.ncbi.nlm.nih.gov/pubmed/35417998 http://dx.doi.org/10.4103/0022-3859.343150

Ejemplares similares

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience
por: Bommannan, KB, et al.
Publicado: (2022)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia
por: Lavoie, Declan C T, et al.
Publicado: (2019)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
por: Ono, Takaaki
Publicado: (2021)

Chronic myeloid leukemia: An Indian scenario
por: Digumarti, Raghunadharao
Publicado: (2016)

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells
por: Mitrovský, Ondřej, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Rapid Sequential Gain of ABL1 Kinase Domain Mutations with a Complex Karyotype in the Progression of Chronic Myelogenous Leukemia
por: Chung, Yousun, et al.
Publicado: (2014)

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
por: Okumura, Lucas M., et al.
Publicado: (2015)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2023)

Will kinase domain mutations dictate the terms…
por: Agarwal, M. B., et al.
Publicado: (2013)

Chronic myeloid leukemia: Review of our Indian experience
por: Bhave, Abhay A.
Publicado: (2013)

The role of early molecular predictor in transplant-eligible chronic myelogenous leukemia
por: Kim, Sung-Hyun
Publicado: (2017)

Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase Inhibitors
por: Soni, Abha, et al.
Publicado: (2016)

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients
por: Rivera, Donna R, et al.
Publicado: (2020)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature
por: Martinez-Cordero, Humberto, et al.
Publicado: (2019)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Acute myeloid leukemia with 3q26 abnormality: An editorial perspective
por: Ghosh, K
Publicado: (2018)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
por: Moschovi, Maria, et al.
Publicado: (2021)

Rare Frameshift Mutation Cys475Tyrfs(*)11 in the BCR/ABL Kinase Domain Contributes to Imatinib Mesylate Resistance in 2 Korean Patients with Chronic Myelogenous Leukemia
por: Park, Sang Hyuk, et al.
Publicado: (2012)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
por: Glodkowska-Mrowka, E, et al.
Publicado: (2016)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

Young-onset diabetes: An Indian perspective
por: Dutta, Deep, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2sche906842s82vkcs92o24b19